Vyvgart a rapid, effective treatment for impending myasthenic crisis
Treatment with Vyvgart (efgartigimod) may rapidly and safely ease symptoms during an impending myasthenic crisis in people with…
Andrea Lobo is a Science writer at Bionews since 2022. She holds a PhD in Cell Biology/Neurosciences, where she studied the molecular pathways that contribute to neurodegeneration/neuroprotection in stroke biology. Between 2011 and 2021, she worked as a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, focused on the molecular mechanisms involved in drug addiction, particularly neuronal plasticity and remodeling induced by amphetamines. As a research scientist for 19 years, Andrea also participated in academic projects in other research fields, including gene regulation, cancer, and rare diseases. During her professional journey, Andrea also developed her science writing skills by writing/editing scientific papers and grant proposals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Treatment with Vyvgart (efgartigimod) may rapidly and safely ease symptoms during an impending myasthenic crisis in people with…
A maintenance regimen using an intravenous immunoglobulin (IVIG) therapy may reduce disease severity and improve function in people with…
The European Medicines Agency granted orphan drug status to the experimental cell therapy KYV-101 to treat myasthenia gravis…
Soliris (eculizumab) effectively eased disease severity and reduced the need for immunosuppressive therapies in people with treatment-resistant generalized…
Myasthenia gravis (MG) patients who are women or have a tumor in the thymus gland are more likely to…
The new UCB Myasthenia Gravis Scholarship, launched by the Belgium-based biopharmaceutical company, is aiming to help myasthenia gravis…
Myasthenia gravis (MG) cases increased gradually from 2000 to 2020 in Denmark, Finland, and Sweden, with the total number…
The case of a 72-year-old man who developed myasthenia gravis (MG) and myocarditis, or inflammation of the heart, following…
Blood levels of specific antibodies that target the muscle-specific tyrosine kinase (MuSK) may be biomarkers of disease severity and treatment…
Johnson & Johnson has submitted an application to the European Medicines Agency (EMA) seeking approval of nipocalimab to…
Get regular updates to your inbox.